MyFinsight
Home
Blog
About
Proceeds from exercise of
stock options and rsus...
$1,973K
(89.35%↑ Y/Y)
Net cash provided by
financing activities
$1,479K
(-97.75%↓ Y/Y)
Canceled cashflow
$494K
Net decrease in
cash, cash...
-$179,810K
(-831.61%↓ Y/Y)
Canceled cashflow
$1,479K
Proceeds from maturities
of marketable...
$31,000K
(-74.59%↓ Y/Y)
Stock-based compensation
expense
$8,318K
(-41.35%↓ Y/Y)
Accrued expenses
$3,180K
(149.04%↑ Y/Y)
Accounts payable
$2,004K
(492.90%↑ Y/Y)
Operating lease
right-of-use assets
$340K
(-69.06%↓ Y/Y)
Depreciation expense
$43K
(-85.52%↓ Y/Y)
Other non-cash items
-$31K
(88.26%↑ Y/Y)
Withholding taxes paid on
stock-based awards
$494K
(-50.00%↓ Y/Y)
Net cash used in
investing activities
-$149,797K
(-624.88%↓ Y/Y)
Net cash used in
operating activities
-$31,424K
(51.71%↑ Y/Y)
Canceled cashflow
$31,000K
Canceled cashflow
$13,916K
Effect of exchange rate
changes on cash, cash...
-$68K
(-108.45%↓ Y/Y)
Purchases of investments
$180,767K
(26.73%↑ Y/Y)
Net loss
-$43,423K
(43.86%↑ Y/Y)
Purchases of property and
equipment
$30K
(7.14%↑ Y/Y)
Accretion of investment
discounts, net
$1,217K
(-62.28%↓ Y/Y)
Operating lease
liabilities
-$375K
(67.62%↑ Y/Y)
Prepaid expenses and
other current assets
$325K
(104.98%↑ Y/Y)
Back
Back
Cash Flow
Amylyx Pharmaceuticals, Inc. (AMLX)
Amylyx Pharmaceuticals, Inc. (AMLX)
source: myfinsight.com